Looking to publish in Gastric Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowGastric Cancer is a high-level global forum dedicated to all areas of research, treatment, and biology relevant to gastric cancer. It welcomes original articles, case reports, short communications, technical notes, and Letters to the Editor, while review articles are primarily solicited by the Editor.
Looking to publish in Gastric Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Gastric Cancer accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Review Articles
Meta-Analysis Studies
Case Reports
Short Communications
Letters To The Editor
Recent Publications
Germline whole-exome sequencing identifies CTNND1 as a candidate gene for hereditary gastric cancer in a large Brazilian cohort
Deivid Calebe de Souza, Thaliane Buranello, Dario Tenorio Tavares Neto, Janina Pontes Pisani, Giovanna Napolitano Pereira Ribeiro, Marcia Olandoski, David Schlesinger, João Paulo Kitajima, Danilo Vilela Viana, Maria Isabel Achatz
A systematic review of factors associated with the patient and diagnostic intervals in gastric cancer
John A. Queenan, Noor Breik, Shaila J. Merchant, Monica Yuen, Ekaterina Kosyachkova, Colleen Webber, Amanda Ross-White, Biniam Kidane, Safiya Karim, Natalie Coburn, Alyson L. Mahar
Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer
Ryota Matsui, Kazuyoshi Yamamoto, Yoshiro Yukawa, Masayoshi Terayama, Yukinori Kurokawa, Daisuke Ichikawa, Yoshitomo Yanagimoto, Takashi Oshima, Souya Nunobe, Takashi Kamei, Hiroya Takeuchi, Yoshihiro Nabeya, Masaki Kaibori, Naoki Hiki, Hidetoshi Eguchi, Yuichiro Doki
Clinicopathological characteristics of gastric papillary adenocarcinoma compared with tubular adenocarcinoma
Taku Hattori, Masanori Terashima, Atsushi Ochiai, Tadakazu Shimoda, Yusuke Koseki, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Etsuro Bando
Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study
Shigenori Kadowaki, Tomoyuki Otsuka, Keiko Minashi, Shinichi Nishina, Hiroshi Yabusaki, Chiaki Inagaki, Tomohiro Nishina, Hisateru Yasui, Hiroshi Matsuoka, Nozomu Machida, Masahiro Tsuda, Fumio Nagashima, Hisashi Hosaka, Junichi Matsubara, Hiroyuki Arai, Satoshi Ida, Yuya Kimijima, Yuko Matsuda, Manabu Muto, Kei Muro
Frequently asked questions
How long does it take to publish?
Prospective randomized controlled trials must be registered within 6 months from first patient enrollment. Articles are published online after receipt of corrected proofs.
Reformat to Gastric Cancer using Livewrite PremiumIs a cover letter required?
A submission letter is referenced for reviewer suggestions and for transparency on reuse of material and unpublished material included in the manuscript.
Reformat to Gastric Cancer using Livewrite PremiumWhat are the publication costs?
Open access APC: £3690.00 GBP / $5690.00 USD / €4390.00 EUR. Subscription publishing has no APC charges.
Reformat to Gastric Cancer using Livewrite Premium